When I looked at RSH briefly this morning I can understand the market’s reluctance to price in revenue until it arrives.
they received FDA clearance two years ago and also have very attractive reimbursement codes for remote asthma monitoring (wheezo) despite lots of positive sounding partners and distributor deals announcements over the last two years they have basically no revenue (100k last qtr) and the shareprice has declined accordingly.
very similar market cap to CDX and two years after FDA not a lot to show for it. Let’s hope CDX can do better
t
Add to My Watchlist
What is My Watchlist?
